Wolff-Parkinson-White syndrome medical therapy

Jump to navigation Jump to search

Wolff-Parkinson-White syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Differentiating Wolff-Parkinson-White syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

Approach

History and Symptoms

Electrocardiogram

EKG Examples

Other Diagnostic Studies

Treatment

Risk Stratification

Cardioversion

Medical Therapy

Catheter Ablation

Prophylaxis

Consensus Statement

Case Studies

Case #1

Wolff-Parkinson-White syndrome medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Wolff-Parkinson-White syndrome medical therapy

CDC onWolff-Parkinson-White syndrome medical therapy

Wolff-Parkinson-White syndrome medical therapy in the news

Blogs on Wolff-Parkinson-White syndrome medical therapy

Directions to Hospitals Treating Deep vein thrombosis

Risk calculators and risk factors for Wolff-Parkinson-White syndrome medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]

Overview

Acutely, people with WPW who are experiencing a tachydysrhythmia may require electrical cardioversion if their condition is critical, or, if more stable, medical treatment may be used. Patients with atrial fibrillation and rapid ventricular response are often treated with amiodarone orprocainamide to stabilize their heart rate. Adenosine and other AV node blockers should be avoided in Atrial fibriliiatin with WPW; this inlcudes adenosine, diltiazem, verapamil,other calcium channel blockers and Beta-blockers. Patients with a rapid heart beat with narrow QRS complexes (circus movement tachycardias) may also be cardioverted, alternatively, adenosine may be administered if equipment for cardioversion is immediately available as a backup.

The definitive treatment of WPW syndrome is a destruction of the abnormal electrical pathway by radiofrequency catheter ablation. This procedure is performed almost exclusively by cardiac electrophysiologists. Radiofrequency catheter ablation is not performed in all individuals with WPW syndrome because there are inherent risks involved in the procedure. Adeosine is contraindicated for patients in atrial fibrillation or atrial flutter with a history of WPW

When performed by an experienced electrophysiologist, radiofrequency ablation has a high success rate.[1] If radiofrequency catheter ablation is successfully performed, the patient is generally considered cured. Recurrence rates are typically less than 5% after a successful ablation.[1] The one caveat is that individuals with underlying Ebstein's anomaly may develop additional accessory pathways during progression of their disease.

Acute Treatment

Atrioventricular Reentrant Tachycardia (AVRT)

  • AVRT is one of the type of tachycardia that can occur in patients with WPW pattern. AVRT can be either orthodromic or antidromic, and the distinction between the two types is important because it dictates the choice of treatment.
  • WPW syndrome patients with AVRT who are hemodynamically unstable, as reflected by hypotension, cold extremities, mottling or peripheral cyanosis, or those who present with ischemic chest pain or decompensated heart failure should urgently undergo direct current cardioversion. The shocks should be delivered as follows:
    • Narrow regular rhythm: synchronized electrical cardioversion, 50-100 Joules
    • Narrow irregular rhythm: synchronized electrical cardioversion, 120-200 Joules biphasic or 200 Joules monophasic
    • Wide regular rhythm: synchronized electrical cardioversion, 100 Joules
    • Wide irregular rhythm: unsynchronized electrical cardioversion, 200-360 J monophasic, or 100-200 J biphasic

Atrial Fibrillation

  • Patients can experience high rates during AFib because of conduction over the accessory pathway which can have a very short refractory period.
  • Mean ventricular rates in these patients range from 160 to 300 BPM.
  • During these attacks there is not only the risk of hemodynamic compromise but also a risk of degenerate into VF.
  • As a rule dig should be avoided in these patients.
  • Cardioversion is the tx of choice. If the patient is receiving drugs that promote asystole following electrical cardioversion (e.g. verapamil, beta-blockers, and probably amiodarone) then a temporary pacer should be positioned in the RV before the cardioversion.
  • If the ventricular rate during the AFib is not > 200, then you could try procainamide, disopyramide, or quinidine which may prolong the refractory period of the accessory pathway.

Long Term Management

Shown below is an EKG of a 24 years old man with Mahaim type of preexcitation.



Shown below is an EKG of the same patient after Mahaim bundle ablation


References

  1. 1.0 1.1 Pappone C, Lamberti F, Santomauro M, Stabile G, De Simone A, Turco P, Pannain S, Loricchio ML, Rotunno R, Chiariello M (1993). "Ablation of paroxysmal tachycardia in Wolff-Parkinson-White syndrome". Cardiologia (in Italian). 38 (12 Suppl 1): 189–97. PMID 8020017.

Template:WH Template:WS